scholarly journals Effect of association with adenylyl cyclase-associated protein on the interaction of yeast adenylyl cyclase with Ras protein.

1997 ◽  
Vol 17 (3) ◽  
pp. 1057-1064 ◽  
Author(s):  
F Shima ◽  
Y Yamawaki-Kataoka ◽  
C Yanagihara ◽  
M Tamada ◽  
T Okada ◽  
...  
Keyword(s):  
Adenylyl Cyclase ◽  
Posttranslational Modification ◽  
Fold Increase ◽  
Terminal Segment ◽  
Amino Acid Residues ◽  
Ras Proteins ◽  
Ras Protein ◽  
Reconstituted System

Posttranslational modification of Ras protein has been shown to be critical for interaction with its effector molecules, including Saccharomyces cerevisiae adenylyl cyclase. However, the mechanism of its action was unknown. In this study, we used a reconstituted system with purified adenylyl cyclase and Ras proteins carrying various degrees of the modification to show that the posttranslational modification, especially the farnesylation step, is responsible for 5- to 10-fold increase in Ras-dependent activation of adenylyl cyclase activity even though it has no significant effect on their binding affinity. The stimulatory effect of farnesylation is found to depend on the association of adenylyl cyclase with 70-kDa adenylyl cyclase-associated protein (CAP), which was known to be required for proper in vivo response of adenylyl cyclase to Ras protein, by comparing the levels of Ras-dependent activation of purified adenylyl cyclase with and without bound CAP. The region of CAP required for this effect is mapped to its N-terminal segment of 168 amino acid residues, which coincides with the region required for the in vivo effect. Furthermore, the stimulatory effect is successfully reconstituted by in vitro association of CAP with the purified adenylyl cyclase molecule lacking the bound CAP. These results indicate that the association of adenylyl cyclase with CAP is responsible for the stimulatory effect of posttranslational modification of Ras on its activity and that this may be the mechanism underlying its requirement for the proper in vivo cyclic AMP response.

scholarly journals Prenylation of mammalian Ras protein in Xenopus oocytes.

1990 ◽  
Vol 10 (11) ◽  
pp. 5945-5949 ◽  
Author(s):  
R Kim ◽  
J Rine ◽  
S H Kim
Keyword(s):  
Biological Activity ◽  
Posttranslational Modification ◽  
Xenopus Oocytes ◽  
Cholesterol Biosynthesis ◽  
Mevalonic Acid ◽  
Xenopus Laevis Oocytes ◽  
Ras Protein ◽  
C Terminus

Ras protein requires an intermediate of the cholesterol biosynthetic pathway for posttranslational modification and membrane anchorage. This step is necessary for biological activity. Maturation of Xenopus laevis oocytes induced by an oncogenic human Ras protein can be inhibited by lovastatin or compactin, inhibitors of the synthesis of mevalonate, an intermediate of cholesterol biosynthesis. This inhibition can be overcome by mevalonic acid or farnesyl diphosphate, a cholesterol biosynthetic intermediate downstream of mevalonate, but not by squalene, an intermediate after farnesyl pyrophosphate in the pathway. This study supports the idea that in Xenopus oocytes, the Ras protein is modified by a farnesyl moiety or its derivative. Furthermore, an octapeptide with the sequence similar to the C-terminus of the c-H-ras protein inhibits the biological activity of Ras proteins in vivo, suggesting that it competes for the enzyme or enzymes responsible for transferring the isoprenoid moiety (prenylation) in the oocytes. This inhibition of Ras prenylation by the peptide was also observed in vitro, using both Saccharomyces cerevisiae and Xenopus oocyte extracts. These observations show that Xenopus oocytes provide a convenient in vivo system for studies of inhibitors of the posttranslational modification of the Ras protein, especially for inhibitors such as peptides that do not penetrate cell membranes.

scholarly journals Mutations in the SHR5 gene of Saccharomyces cerevisiae suppress Ras function and block membrane attachment and palmitoylation of Ras proteins.

1995 ◽  
Vol 15 (3) ◽  
pp. 1333-1342 ◽  
Author(s):  
V Jung ◽  
L Chen ◽  
S L Hofmann ◽  
M Wigler ◽  
S Powers
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Current Data ◽  
Ras Proteins ◽  
Wild Type ◽  
Yeast Saccharomyces Cerevisiae ◽  
Ras Protein ◽  
Membrane Attachment ◽  
Extragenic Suppressors

We have identified a gene, SHR5, in a screen for extragenic suppressors of the hyperactive RAS2Val-19 mutation in the budding yeast Saccharomyces cerevisiae. SHR5 was cloned, sequenced, and found to encode a 23-kDa protein not significantly homologous to other proteins in the current data bases. Genetic evidence arguing that Shr5 operates at the level of Ras is presented. We tested whether SHR5, like previously isolated suppressors of hyperactivated RAS2, acts by affecting the membrane attachment and/or posttranslational modification of Ras proteins. We found that less Ras protein is attached to the membrane in shr5 mutants than in wild-type cells and that the Ras proteins are markedly underpalmitoylated, suggesting that Shr5 is involved in palmitoylation of Ras proteins. However, shr5null mutants exhibit normal palmitoyltransferase activity measured in vitro. Further, shr5null mutations attenuate Ras function in cells containing mutant Ras2 proteins that are not palmitoylated or farnesylated. We conclude that SHR5 encodes a protein that participates in the membrane localization of Ras but also interacts in vivo with completely unprocessed and cytosolic Ras proteins.

scholarly journals Posttranslational modification of the RHO of plants protein RACB by phosphorylation and cross-kingdom conserved ubiquitination

2020 ◽  
Author(s):  
Lukas Weiß ◽  
Tina Reiner ◽  
Julia Mergner ◽  
Bernhard Kuster ◽  
Attila Fehér ◽  
...  
Keyword(s):  
Amino Acid ◽  
Posttranslational Modification ◽  
Individual Case ◽  
Bound State ◽  
Amino Acid Residues ◽  
Nucleotide Exchange ◽  
Protein Activity ◽  
Developmental Defects

AbstractSmall RHO-type G-proteins act as signaling hubs and master regulators of polarity in eukaryotic cells. Their activity is tightly controlled, as defective RHO signaling leads to aberrant growth and developmental defects. Two major pathways regulate G-protein activity: canonical switching of the nucleotide bound state and posttranslational modification (PTM). PTMs can support or suppress RHO signaling, depending on each individual case. In plants, regulation of Rho of plants (ROPs) has been shown to act through nucleotide exchange and hydrolysis, as well as through lipid modification, but there is little data available on phosphorylation or ubiquitination of ROPs. Hence, we applied proteomic analyses to identify PTMs of the barley ROP RACB. We observed in vitro phosphorylation by barley ROP Binding Kinase 1 and in vivo ubiquitination of RACB. Comparative analyses of the newly identified RACB phosphosites and human RHO protein phosphosites revealed conservation of modified amino acid residues, but no overlap of actual phosphorylation patterns. However, the identified RACB ubiquitination site is present in all ROPs from Hordeum vulgare, Arabidopsis thaliana and Oryza sativa. Since this highly conserved amino acid residue is likewise ubiquitinated in mammalian Rac1 and Rac3, we suggest that RHO family proteins from different kingdoms could be generally regulated by ubiquitination of this site.

scholarly journals A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity.

1992 ◽  
Vol 12 (2) ◽  
pp. 631-637 ◽  
Author(s):  
K Tanaka ◽  
D R Wood ◽  
B K Lin ◽  
M Khalil ◽  
F Tamanoi ◽  
...  
Keyword(s):  
Adenylate Cyclase ◽  
Biochemical Properties ◽  
Negative Regulator ◽  
Ras Proteins ◽  
Vitro Assay ◽  
Ras Protein ◽  
Ras Genes ◽  
Activating Mutation

Previously described mutations in RAS genes that cause a dominant activated phenotype affect the intrinsic biochemical properties of RAS proteins, either decreasing the intrinsic GTPase or reducing the affinity for guanine nucleotides. In this report, we describe a novel activating mutation in the RAS2 gene of Saccharomyces cerevisiae that does not alter intrinsic biochemical properties of the mutant RAS2 protein. Rather, this mutation, RAS2-P41S (proline 41 to serine), which lies in the effector region of RAS, is shown to abolish the ability of the IRA2 protein to stimulate the GTPase activity of the mutant RAS protein. This mutation also modestly reduced the ability of the mutant protein to stimulate the target adenylate cyclase in an in vitro assay, although in vivo the phenotypes it induced suggest that it retains potency in stimulation of adenylate cyclase. Our results demonstrate that although the effector region of RAS appears to be important for interaction with both target effector and negative regulators of RAS, it is possible to eliminate negative regulator responsiveness and retain potency in effector stimulation.

scholarly journals Identification of amino acid residues required for Ras p21 target activation.

1991 ◽  
Vol 11 (8) ◽  
pp. 3997-4004 ◽  
Author(s):  
M S Marshall ◽  
L J Davis ◽  
R D Keys ◽  
S D Mosser ◽  
W S Hill ◽  
...  
Keyword(s):  
Biological Activity ◽  
Amino Acid ◽  
Protein Interactions ◽  
Amino Acid Residues ◽  
Ras Proteins ◽  
Protein Protein Interactions ◽  
Biological Assays ◽  
Ras P21

The Krev-1 gene has been shown to suppress ras-mediated transformation in vitro. Both ras and Krev-1 proteins have identical effector domains (ras residues 32 to 40), which are required for biological activity and for the interaction of Ras p21 with Ras GTPase-activating protein (GAP). In this study, five amino acid residues flanking the ras effector domain, which are not conserved with the Krev-1 protein, were shown to be required for normal protein-protein interactions and biological activity. The substitution of Krev-1 p21 residues 26, 27, 30, 31, and 45 with the corresponding amino acid residues from Ras p21 resulted in a Krev-1 protein which had ras function in both mammalian and yeast biological assays. Replacement of these residues in Ras p21 with the corresponding Krev-1 p21 amino acids resulted in ras proteins which were impaired biologically or reduced in their affinity for in vitro GAP binding. Evaluation of these mutant ras proteins have implications for Ras p21-GAP interactions in vivo.

scholarly journals Structural Basis of Stu2 Recruitment to Yeast Kinetochores

2020 ◽  
Author(s):  
Jacob A. Zahm ◽  
Michael G. Stewart ◽  
Joseph S. Carrier ◽  
Stephen C. Harrison ◽  
Matthew P. Miller
Keyword(s):  
Cell Cycle Progression ◽  
Spindle Assembly Checkpoint ◽  
Terminal Segment ◽  
Structural Basis ◽  
Amino Acid Residues ◽  
Checkpoint Signaling ◽  
Delay Cell ◽  
Sister Chromatids

ABSTRACTAccurate chromosome segregation during cell division requires engagement of the kinetochores of sister chromatids with microtubules emanating from opposite poles of the mitotic spindle. In yeast, these “bioriented” metaphase sister chromatids experience tension as the corresponding microtubules (one per sister chromatid) shorten. Spindle-assembly checkpoint signaling appears to cease from a kinetochore under tension, which also stabilizes kinetochore-microtubule attachment in single-kinetochore experiments in vitro. The microtubule polymerase, Stu2, the yeast member of the XMAP215/ch-TOG protein family, associates with kinetochores in cells and contributes to tension-dependent stabilization, both in vitro and in vivo. We show here that a C-terminal segment of Stu2 binds the four-way junction of the Ndc80 complex (Ndc80c) and that amino-acid residues conserved both in yeast Stu2 orthologs and in their metazoan counterparts make specific contacts with Ndc80 and Spc24. Mutations that perturb this interaction prevent association of Stu2 with kinetochores, impair cell viability, produce biorientation defects, and delay cell-cycle progression. Ectopic tethering of the mutant Stu2 species to the Ndc80c junction restores wild-type function. These findings show that the role of Stu2 in tension sensing depends on its association with kinetochores by binding with Ndc80c.

Identification of amino acid residues required for Ras p21 target activation

1991 ◽  
Vol 11 (8) ◽  
pp. 3997-4004
Author(s):  
M S Marshall ◽  
L J Davis ◽  
R D Keys ◽  
S D Mosser ◽  
W S Hill ◽  
...  
Keyword(s):  
Biological Activity ◽  
Amino Acid ◽  
Protein Interactions ◽  
Amino Acid Residues ◽  
Ras Proteins ◽  
Protein Protein Interactions ◽  
Biological Assays ◽  
Ras P21

The Krev-1 gene has been shown to suppress ras-mediated transformation in vitro. Both ras and Krev-1 proteins have identical effector domains (ras residues 32 to 40), which are required for biological activity and for the interaction of Ras p21 with Ras GTPase-activating protein (GAP). In this study, five amino acid residues flanking the ras effector domain, which are not conserved with the Krev-1 protein, were shown to be required for normal protein-protein interactions and biological activity. The substitution of Krev-1 p21 residues 26, 27, 30, 31, and 45 with the corresponding amino acid residues from Ras p21 resulted in a Krev-1 protein which had ras function in both mammalian and yeast biological assays. Replacement of these residues in Ras p21 with the corresponding Krev-1 p21 amino acids resulted in ras proteins which were impaired biologically or reduced in their affinity for in vitro GAP binding. Evaluation of these mutant ras proteins have implications for Ras p21-GAP interactions in vivo.

Prenylation of mammalian Ras protein in Xenopus oocytes

1990 ◽  
Vol 10 (11) ◽  
pp. 5945-5949
Author(s):  
R Kim ◽  
J Rine ◽  
S H Kim
Keyword(s):  
Biological Activity ◽  
Posttranslational Modification ◽  
Xenopus Oocytes ◽  
Cholesterol Biosynthesis ◽  
Mevalonic Acid ◽  
Xenopus Laevis Oocytes ◽  
Ras Protein ◽  
C Terminus

Ras protein requires an intermediate of the cholesterol biosynthetic pathway for posttranslational modification and membrane anchorage. This step is necessary for biological activity. Maturation of Xenopus laevis oocytes induced by an oncogenic human Ras protein can be inhibited by lovastatin or compactin, inhibitors of the synthesis of mevalonate, an intermediate of cholesterol biosynthesis. This inhibition can be overcome by mevalonic acid or farnesyl diphosphate, a cholesterol biosynthetic intermediate downstream of mevalonate, but not by squalene, an intermediate after farnesyl pyrophosphate in the pathway. This study supports the idea that in Xenopus oocytes, the Ras protein is modified by a farnesyl moiety or its derivative. Furthermore, an octapeptide with the sequence similar to the C-terminus of the c-H-ras protein inhibits the biological activity of Ras proteins in vivo, suggesting that it competes for the enzyme or enzymes responsible for transferring the isoprenoid moiety (prenylation) in the oocytes. This inhibition of Ras prenylation by the peptide was also observed in vitro, using both Saccharomyces cerevisiae and Xenopus oocyte extracts. These observations show that Xenopus oocytes provide a convenient in vivo system for studies of inhibitors of the posttranslational modification of the Ras protein, especially for inhibitors such as peptides that do not penetrate cell membranes.

A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity

1992 ◽  
Vol 12 (2) ◽  
pp. 631-637
Author(s):  
K Tanaka ◽  
D R Wood ◽  
B K Lin ◽  
M Khalil ◽  
F Tamanoi ◽  
...  
Keyword(s):  
Adenylate Cyclase ◽  
Biochemical Properties ◽  
Negative Regulator ◽  
Ras Proteins ◽  
Vitro Assay ◽  
Ras Protein ◽  
Ras Genes ◽  
Activating Mutation

Previously described mutations in RAS genes that cause a dominant activated phenotype affect the intrinsic biochemical properties of RAS proteins, either decreasing the intrinsic GTPase or reducing the affinity for guanine nucleotides. In this report, we describe a novel activating mutation in the RAS2 gene of Saccharomyces cerevisiae that does not alter intrinsic biochemical properties of the mutant RAS2 protein. Rather, this mutation, RAS2-P41S (proline 41 to serine), which lies in the effector region of RAS, is shown to abolish the ability of the IRA2 protein to stimulate the GTPase activity of the mutant RAS protein. This mutation also modestly reduced the ability of the mutant protein to stimulate the target adenylate cyclase in an in vitro assay, although in vivo the phenotypes it induced suggest that it retains potency in stimulation of adenylate cyclase. Our results demonstrate that although the effector region of RAS appears to be important for interaction with both target effector and negative regulators of RAS, it is possible to eliminate negative regulator responsiveness and retain potency in effector stimulation.

Oxytocin analogues with non-coded amino acid residues in position 8: [8-Neopentylglycine]oxytocin and [8-cycloleucine]oxytocin

1987 ◽  
Vol 52 (9) ◽  
pp. 2317-2325 ◽  
Author(s):  
Jan Hlaváček ◽  
Jan Pospíšek ◽  
Jiřina Slaninová ◽  
Walter Y. Chan ◽  
Victor J. Hruby
Keyword(s):  
Amino Acid ◽  
Solid Phase Synthesis ◽  
Solid Phase ◽  
The Other ◽  
Amino Acid Residues ◽  
Phase Synthesis ◽  
Other Hand ◽  
Fragment Condensation

[8-Neopentylglycine]oxytocin (II) and [8-cycloleucine]oxytocin (III) were prepared by a combination of solid-phase synthesis and fragment condensation. Both analogues exhibited decreased uterotonic potency in vitro, each being about 15-30% that of oxytocin. Analogue II also displayed similarly decreased uterotonic potency in vivo and galactogogic potency. On the other hand, analogue III exhibited almost the same potency as oxytocin in the uterotonic assay in vivo and in the galactogogic assay.

Sign in / Sign up

Export Citation Format

Share Document